Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

Nishi Kothari, Richard Kim, Robert N. Jorissen, Jayesh Desai, Jeanne Tie, Hui Li Wong, Ian Farragher, Ian Jones, Fiona L. Day, Shan Li, Anuratha Sakthinandeswaren, Michelle Palmieri, Lara Lipton, Michael Schell, Jamie K. Teer, David Shibata, Timothy Yeatman, Oliver M. Sieber, Peter Gibbs, Ben Tran

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background. Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations. However, the number of PIK3CA-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with PIK3CA-mutated CRC. Patients and methods. Patients with PIK3CA-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, PIK3CA mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression. Results. From a cohort of 1487 CRC patients, 185 patients harbored a PIK3CA mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34-92) and median follow up was 54 months. Forty-nine (26%) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant. Conclusions. Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.

Original languageEnglish (US)
Pages (from-to)487-492
Number of pages6
JournalActa Oncologica
Volume54
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Aspirin
Colorectal Neoplasms
Mutation
Survival
Neoplasms
Exome
Survival Analysis
Multivariate Analysis
Logistic Models

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. / Kothari, Nishi; Kim, Richard; Jorissen, Robert N.; Desai, Jayesh; Tie, Jeanne; Wong, Hui Li; Farragher, Ian; Jones, Ian; Day, Fiona L.; Li, Shan; Sakthinandeswaren, Anuratha; Palmieri, Michelle; Lipton, Lara; Schell, Michael; Teer, Jamie K.; Shibata, David; Yeatman, Timothy; Sieber, Oliver M.; Gibbs, Peter; Tran, Ben.

In: Acta Oncologica, Vol. 54, No. 4, 01.04.2015, p. 487-492.

Research output: Contribution to journalArticle

Kothari, N, Kim, R, Jorissen, RN, Desai, J, Tie, J, Wong, HL, Farragher, I, Jones, I, Day, FL, Li, S, Sakthinandeswaren, A, Palmieri, M, Lipton, L, Schell, M, Teer, JK, Shibata, D, Yeatman, T, Sieber, OM, Gibbs, P & Tran, B 2015, 'Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation', Acta Oncologica, vol. 54, no. 4, pp. 487-492. https://doi.org/10.3109/0284186X.2014.990158
Kothari, Nishi ; Kim, Richard ; Jorissen, Robert N. ; Desai, Jayesh ; Tie, Jeanne ; Wong, Hui Li ; Farragher, Ian ; Jones, Ian ; Day, Fiona L. ; Li, Shan ; Sakthinandeswaren, Anuratha ; Palmieri, Michelle ; Lipton, Lara ; Schell, Michael ; Teer, Jamie K. ; Shibata, David ; Yeatman, Timothy ; Sieber, Oliver M. ; Gibbs, Peter ; Tran, Ben. / Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. In: Acta Oncologica. 2015 ; Vol. 54, No. 4. pp. 487-492.
@article{e7b78a40dddd47de8aaf585c3c510262,
title = "Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation",
abstract = "Background. Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations. However, the number of PIK3CA-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with PIK3CA-mutated CRC. Patients and methods. Patients with PIK3CA-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, PIK3CA mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression. Results. From a cohort of 1487 CRC patients, 185 patients harbored a PIK3CA mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34-92) and median follow up was 54 months. Forty-nine (26{\%}) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant. Conclusions. Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.",
author = "Nishi Kothari and Richard Kim and Jorissen, {Robert N.} and Jayesh Desai and Jeanne Tie and Wong, {Hui Li} and Ian Farragher and Ian Jones and Day, {Fiona L.} and Shan Li and Anuratha Sakthinandeswaren and Michelle Palmieri and Lara Lipton and Michael Schell and Teer, {Jamie K.} and David Shibata and Timothy Yeatman and Sieber, {Oliver M.} and Peter Gibbs and Ben Tran",
year = "2015",
month = "4",
day = "1",
doi = "10.3109/0284186X.2014.990158",
language = "English (US)",
volume = "54",
pages = "487--492",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

AU - Kothari, Nishi

AU - Kim, Richard

AU - Jorissen, Robert N.

AU - Desai, Jayesh

AU - Tie, Jeanne

AU - Wong, Hui Li

AU - Farragher, Ian

AU - Jones, Ian

AU - Day, Fiona L.

AU - Li, Shan

AU - Sakthinandeswaren, Anuratha

AU - Palmieri, Michelle

AU - Lipton, Lara

AU - Schell, Michael

AU - Teer, Jamie K.

AU - Shibata, David

AU - Yeatman, Timothy

AU - Sieber, Oliver M.

AU - Gibbs, Peter

AU - Tran, Ben

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background. Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations. However, the number of PIK3CA-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with PIK3CA-mutated CRC. Patients and methods. Patients with PIK3CA-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, PIK3CA mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression. Results. From a cohort of 1487 CRC patients, 185 patients harbored a PIK3CA mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34-92) and median follow up was 54 months. Forty-nine (26%) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant. Conclusions. Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.

AB - Background. Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring PIK3CA mutations. However, the number of PIK3CA-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with PIK3CA-mutated CRC. Patients and methods. Patients with PIK3CA-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, PIK3CA mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression. Results. From a cohort of 1487 CRC patients, 185 patients harbored a PIK3CA mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34-92) and median follow up was 54 months. Forty-nine (26%) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant. Conclusions. Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84925446564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925446564&partnerID=8YFLogxK

U2 - 10.3109/0284186X.2014.990158

DO - 10.3109/0284186X.2014.990158

M3 - Article

VL - 54

SP - 487

EP - 492

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 4

ER -